Navigation Links
Color Slide RF

ProductsColor Slide RF
Company Remel Inc.
Item Color Slide RF
Features Inquire
Description Rapid latex slide agglutination assay for the qualitative and semi-quantitative determination of Rheumatoid Factors in human serum.
Info Remel Inc.
Customer Service: (800) 255-6730
Web site: http://www.remel.com

Related medicine products :

1. LAnthony New Color Test 100 Hue Test
2. Ishihara Color Test
3. Ishihara Color Blindness Test
4. Wildeyes X-Colors
5. Freshlook Colors
6. Freshlook Color Enhancers
7. Freshlook Colorblends
8. Durasoft 2 Colorblends
9. Durasoft 2 Colors
10. Durasoft 2 Colors for Light Eyes
11. Durasoft 3 Colors
TAG: Color Slide
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
Medicine Products:
(Date:10/10/2008)...ewswire/ -- Public interest,advocates(1) welcomed ...ecisions on the threats posed by mercury to human ...2nd UNEP(2) Open Ended Working Group (OEWG2) on,Me...of a global framework,on mercury, in preparation f...9, where it will be decided whether a global legal...
(Date:10/10/2008)...ame , , FRIDAY, Oct. 10 (HealthDay News)...diabetes, being depressed was associated with a hi...Publishing in the October issue of the Journal of...University of Washington tracked 10,704 Medicare b...iabetes and were enrolled in a disease management ...
(Date:10/10/2008)...eening for these patients, researcher says , ...s coping with metabolic syndrome have a 75 percent...time in their lives, a new study suggests. , "M...four diseases, that together can portend a worse p... of cancers," said study co-author Dr. Donald Garr...
(Date:10/10/2008)...nce in the implementation of electronic health rec...ment Systems Society (HIMSS) announces the recipie...l, Ambulatory and Community Health Organization ca...PRWEB) October 10, 2008 -- Honoring excellence in ...HRs), the Healthcare Information and Management S...
Breaking Medicine News(10 mins):Health News:Elements for a UN Global Framework on Mercury Agreed to 2Health News:Older Diabetics With Depression Face Higher Death Rate 2Health News:Metabolic Syndrome Raises Colon Cancer Risk 75% 2Health News:Metabolic Syndrome Raises Colon Cancer Risk 75% 3Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 3Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 4Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 5
...gs, maintained by teenagers from age 13 to 17, has...provide personal information, //thus making them v...faker, a Northwestern University researcher, invol..., will be presenting the study on Teenage Internet...
...isease. Immune cells destroy the myelin sheath th...cord. // The myelin is very essential in transmitt...ele University, Staffordshire, compared the levels...he urine of people with MS and others without the ...
...at the euthanasia campaigner Dr Philip Nitschke do...n New Zealand. // The workshop informs participant...But the Council said that Dr Nitschke needs to be ...ry out his euthanasia workshops. On the other han...
...um, the UNAIDS and UNICEF Special Representative f...of education, in bettering the lot of the children...the anti-Aids movement a morale boost. The Prince...East African Country said 'During the past days, I...
Other Medicine News:Health News:Teens need to Exercise Caution While Using Online Blogs 2Health News:Aluminium and Iron Could Play a Vital Role in Multiple Sclerosis 2
(Date:10/8/2008)...RNewswire/ -- Vical Incorporated (Nasdaq: VICL ),... nonclinical data,demonstrating that the company,s...n DNA- and protein-based infectious disease vaccin...land, Pharm.D., Ph.D., Vical,s,Senior Vice Preside...oday,Wednesday, October 8, at the World Vaccine C...
(Date:10/7/2008)...- The Texas Cardiac Arrhythmia,Instit...selected as one of,only a few sites in the nation ...or a new device to treat persistent atrial fibrill...and research center specializing in heart,rhythm d...ical Center and,Texas Cardiovascular Consultants.,...
(Date:10/7/2008)...adults, VYVANSE taken once-daily significantly,imp...DELPHIA, Oct. 7 /- Shire pl...biopharmaceutical company, today,announced that a ...nal of,Clinical Psychiatry found once-daily VYVANS...tivity Disorder (ADHD) symptoms in adults within,t...
(Date:10/7/2008)...ighting CIMZIA,s long-term benefits and value in,m...ed at American College,of Gastroenterology (ACG), ...ta from two studies,presented this week by UCB at ...ual Meeting demonstrate that CIMZIA(R) (certolizum...or Necrosis Factor alpha) - provides,sustained imp...
Breaking Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Time For the Trucking and Heavy Machinery Industries to Wake Up 21 388 1Time For the Trucking and Heavy Machinery Industries to Wake Up 21 388 2Time For the Trucking and Heavy Machinery Industries to Wake Up 21 388 3Time For the Trucking and Heavy Machinery Industries to Wake Up 21 388 4Time For the Trucking and Heavy Machinery Industries to Wake Up 21 388 5BDSI secures US commercial partnership for BEMA Fentanyl with Meda AB 574 1BDSI secures US commercial partnership for BEMA Fentanyl with Meda AB 574 2BDSI secures US commercial partnership for BEMA Fentanyl with Meda AB 574 3Homeowners Admit to Dust Bunny Dilemma 570 1Homeowners Admit to Dust Bunny Dilemma 570 2Homeowners Admit to Dust Bunny Dilemma 570 3Homeowners Admit to Dust Bunny Dilemma 570 4Homeowners Admit to Dust Bunny Dilemma 570 5First Ever List of the 5 000 Fastest Growing Businesses Reports Total Revenue of 24194 5 Billion 566 1First Ever List of the 5 000 Fastest Growing Businesses Reports Total Revenue of 24194 5 Billion 566 2First Ever List of the 5 000 Fastest Growing Businesses Reports Total Revenue of 24194 5 Billion 566 3First Ever List of the 5 000 Fastest Growing Businesses Reports Total Revenue of 24194 5 Billion 566 4
...Demonstrates 50% Survival in Valortim-Treated Anim...9, 2007,/PRNewswire-FirstCall/ -- Medarex, Inc. , ...hene, Inc., a privately held,biotechnology company...rmeasures, today announced that Valortim(TM), a fu...ing developed for the,prevention and treatment of ...
...SINESS WIRE)--Mar 29, 2007 - Cytogen,Corporation (...tion,of preclinical data at the 2007 Annual Meetin...(AACR) taking place in Los Angeles,California Apr...eclinical studies that validate novel approaches t...ompany,s proprietary,Abtides(TM) (Antigen-Binding ...
Other Medicine Technology:Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 2Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 3Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 4Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 5Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 6Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 7Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 8Preclinical Data on Cytogen's Technology to be Reported at the AACR,Annual Meeting 2Preclinical Data on Cytogen's Technology to be Reported at the AACR,Annual Meeting 3Preclinical Data on Cytogen's Technology to be Reported at the AACR,Annual Meeting 4